GSK对其在HIV市场的主要竞争对手吉列德再次发起猛烈攻击。 近日，在慕尼黑举行的AIDS 2024大会上，GSK分享了其Dovato与吉利德的Biktary在治疗HIV上的头 ...

吉利德科学（Gilead）凭借新获批的半年期 HIV 预防药物 Yeztugo，正式向市场霸主地位发起冲击。这款长效注射剂每六个月给药一次，相较现有每日口服药 Descovy 和 GSK 旗下每两个月注射一次的 Apretude，大幅提升了用药便利性。分析师预测，Yeztugo 的峰值销售额可能达到 45 亿美元，成为 HIV 预防领域的新标杆。

MPP执行董事Charles Gore指出，该组织此前与ViiV就多替拉韦达成的协议已使129个国家能够获得基于DTG的仿制HIV治疗药物，他补充说，他们希望"CAB LA能够实现类似的覆盖范围"。想要深入了解葛兰素史克的财务健康状况和增长潜力？ InvestingPro 订阅者可以获取超过30项额外的财务指标和专家分析，包括独家ProTips和全面的研究报告。

GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK, said on Monday it has expanded its licensing deal with the Medicines Patent Pool to allow generic production of its long-acting ...

A human trial into a potential cure for HIV will commence in 2022, United Kingdom pharmaceutical company GSK has announced, after the treatment gained encouraging results from animal testing.

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and ...

The booth of GSK. [Photo/IC] People living with HIV and people with potential exposure to HIV in China are expected to leverage more of GlaxoSmithKline's innovative research results for the ...

Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.